Excessive synaptic loss is thought to be one of the earliest events in Alzheimer's disease.
Amyloid beta (Aβ), a peptide secreted in an activity-modulated manner by neurons, has …

Compelling experimental evidence suggests that microglial activation is involved in the
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …

Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is
known about proteome-wide changes in microglia during the course of AD and their …

Synapse loss in Alzheimer's disease (AD) correlates with cognitive decline. Involvement of
microglia and complement in AD has been attributed to neuroinflammation, prominent late in …

Alzheimer's disease (AD) predominantly occurs as a late onset (LOAD) form involving
neurodegeneration and cognitive decline with progressive memory loss. Risk factors that …

As the average age of the population continues to rise, the number of individuals affected
with age-related cognitive decline and Alzheimer's disease (AD) has increased and is …

The human brain vasculature is of great medical importance: its dysfunction causes
disability and death, and the specialized structure it forms—the blood–brain barrier …

There is considerable debate whether Alzheimer's disease (AD) originates in basal
forebrain or entorhinal cortex. Here we examined whether longitudinal decreases in basal …

Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

Dementia is a rapidly rising global health crisis that silently disables families and ends lives
and livelihoods around the world. To date, however, no early biomarkers or effective …